Inventor · disambiguated record
Jiang Long
Also filed as: LONG JIANG
48 granted patents·20 pending applications·236 citations·filing 2008–2025
98Inventor score
Top patents by PatentIndex Score
68 records- 0198US11560368B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Jan 24, 2023·6 cites·18 claims
- 0298US10683279B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Jun 16, 2020·13 cites·18 claims
- 0397US11420976B2Heterocyclic compounds as anti-viral agentsENANTA PHARM INC·Filed 2021·Granted Aug 23, 2022·7 cites·23 claims
- 0497US10988458B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2020·Granted Apr 27, 2021·7 cites·23 claims
- 0597US9085599B22′allene-substituted nucleoside derivativesOR YAT SUN·Filed 2012·Granted Jul 21, 2015·45 cites·21 claims
- 0695US10968249B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2020·Granted Apr 6, 2021·3 cites·12 claims
- 0795US10584145B2Process for preparation of sulfonylurea bile acid derivativesENANTA PHARM INC·Filed 2017·Granted Mar 10, 2020·8 cites·14 claims
- 0895US10450301B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Oct 22, 2019·11 cites·20 claims
- 0995US10246439B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Apr 2, 2019·12 cites·20 claims
- 1094US12018017B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2022·Granted Jun 25, 2024·1 cites·14 claims
- 1194US11834436B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Dec 5, 2023·2 cites·5 claims
- 1294US10253018B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Apr 9, 2019·10 cites·26 claims
- 1393US10696713B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Jun 30, 2020·3 cites·15 claims
- 1492US10208081B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2015·Granted Feb 19, 2019·9 cites·53 claims
- 1591US10457703B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2016·Granted Oct 29, 2019·8 cites·16 claims
- 1691US8648037B2Macrocyclic proline derived HCV serine protease inhibitorsOR YAT SUN·Filed 2011·Granted Feb 11, 2014·12 cites·255 claims
- 1791US8367618B2Cyclosporin analogues for preventing or treating hepatitis C infectionENANTA PHARM INC·Filed 2010·Granted Feb 5, 2013·6 cites·13 claims
- 1889US11718641B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Aug 8, 2023·1 cites·5 claims
- 1989US11040998B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2019·Granted Jun 22, 2021·2 cites·17 claims
- 2088US11958879B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Apr 16, 2024·1 cites·5 claims
- 2188US10080743B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·4 cites·22 claims
- 2287US10472386B2Bile acid derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Nov 12, 2019·6 cites·10 claims
- 2387US10080742B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·3 cites·24 claims
- 2487US9220748B2Macrocyclic proline derived HCV serine protease inhibitorsENANTA PHARM INC·Filed 2014·Granted Dec 29, 2015·6 cites·15 claims
- 2585US12281140B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2023·Granted Apr 22, 2025·0 cites·8 claims
- 2685US10149835B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Dec 11, 2018·2 cites·18 claims
- 2785US10080741B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·3 cites·19 claims
- 2885US8481483B2Cyclosporin analoguesOR YAT SUN·Filed 2010·Granted Jul 9, 2013·9 cites·21 claims
- 2985US8367053B2Cyclosporin analoguesENANTA PHARM INC·Filed 2010·Granted Feb 5, 2013·9 cites·18 claims
- 3084US12459923B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2023·Granted Nov 4, 2025·0 cites·12 claims
- 3181US11008304B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2019·Granted May 18, 2021·1 cites·6 claims
- 3280US10144729B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Dec 4, 2018·2 cites·20 claims
- 3380US8623814B2Antiviral agentsOR YAT SUN·Filed 2011·Granted Jan 7, 2014·5 cites·13 claims
- 3480US2024327452A1Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use ThereofENANTA PHARM INC·Filed 2024·Application pending·0 cites
- 3579US2020270303A1Macrocyclic proline derived hcv serine protease inhibitorsENANTA PHARM INC·Filed 2019·Application pending·0 cites
- 3678US9221878B2Cyclosporin analogues for preventing or treating hepatitis C infectionENANTA PHARM INC·Filed 2014·Granted Dec 29, 2015·3 cites·15 claims
- 3778US8921573B2Processes for the preparation of novel benzimidazole derivativesENANTA PHARM INC·Filed 2014·Granted Dec 30, 2014·2 cites·15 claims
- 3878US8349312B2Proline substituted cyclosporin analoguesENANTA PHARM INC·Filed 2010·Granted Jan 8, 2013·4 cites·18 claims
- 3977US8906853B2[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infectionENANTA PHARM INC·Filed 2013·Granted Dec 9, 2014·2 cites·12 claims
- 4076US9156886B2Cyclosporin analogues for preventing or treating hepatitis C infectionENANTA PHARM INC·Filed 2013·Granted Oct 13, 2015·2 cites·13 claims
- 4176US8354383B26,11-bridged biaryl macrolidesENANTA PHARM INC·Filed 2009·Granted Jan 15, 2013·1 cites·34 claims
- 4274US10138228B2Isoxazole derivatives as FXR agonists and methods of use therofENANTA PHARM INC·Filed 2017·Granted Nov 27, 2018·1 cites·18 claims
- 4372US8685917B2Cyclosporin analoguesGAO XURI·Filed 2010·Granted Apr 1, 2014·4 cites·18 claims
- 4471US12384753B217-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2022·Granted Aug 12, 2025·0 cites·6 claims
- 4570US2025376452A117-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use ThereofENANTA PHARM INC·Filed 2025·Application pending·0 cites
- 4668US2024327334A1Covalent Inhibitors As Antiviral AgentsENANTA PHARM INC·Filed 2023·Application pending·0 cites
- 4767US2019263860A1Macrocyclic proline derived hcv serine protease inhibitorsENANTA PHARM INC·Filed 2018·Application pending·0 cites
- 4866US2024207224A1Macrocyclic chalcone-amide derived antiviral agentsENANTA PHARM INC·Filed 2023·Application pending·0 cites
- 4965US2025154163A1Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 InhibitorsENANTA PHARM INC·Filed 2024·Application pending·0 cites
- 5065US2018162905A1Macrocyclic proline derived hcv serine protease inhibitorsENANTA PHARM INC·Filed 2017·Application pending·0 cites
Showing the top 50 of 68 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jiang Long files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →